Premium
At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy
Author(s) -
Intlekofer Andrew M.,
Thompson Craig B.
Publication year - 2013
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.1212621
Subject(s) - blockade , immune system , immunotherapy , ctla 4 , biology , cancer immunotherapy , blocking antibody , cancer research , immunology , receptor , cancer , t cell , immune checkpoint , effector , antibody , biochemistry , genetics
Basic Research Review for Clinicians: The cellular and molecular mechanisms of CTLA‐4 and PD‐1 function, and implications for tumor immunotherapy.